L. Wang-Smith

Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment

W. Wilkison, B. Cheatham, R. Dobbins, 2015, Drug Metabolism and Disposition.

Pharmacokinetics of Treprostinil Diolamine in Subjects With End-Stage Renal Disease On or Off Dialysis

T. Marbury, L. Wang-Smith, A. Jenkins, 2013, Journal of cardiovascular pharmacology.

Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK)

M. Campos, C. Strange, M. Brantly, 2013, COPD.

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study

M. Campos, C. Strange, G. Turino, 2010, BMC clinical pharmacology.

Pharmacokinetics and Relative Bioavailability of a Fixed‐Dose Combination of Enteric‐Coated Naproxen and Non‐Enteric‐Coated Esomeprazole Magnesium

M. Sostek, L. Wang-Smith, Ying Zhang, 2012, Journal of clinical pharmacology.

The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers

J. Kates, L. Wang-Smith, A. Laurent, 2013, Journal of clinical pharmacy and therapeutics.

Pharmacokinetics of 3 Times a Day Dosing of Oral Treprostinil in Healthy Volunteers

Amanda Jones, L. Wang-Smith, Theresa T. Pham, 2014, Journal of cardiovascular pharmacology.

Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK)

C. Strange, M. Brantly, J. Stocks, 2013, COPD.